Drug
Rilvegostomig
Rilvegostomig: highest development phase Phase 2, developed by AstraZeneca. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rilvegostomig NCT07098338 | Phase 2 | Non-Small Cell Lung Cancer |
| Rilvegostomig NCT05702229 | Phase 2 | Gastric Cancer |
Latest
No recent events.
Follow Rilvegostomig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.